Myocardial Work Indices Predict Hospitalization in Patients with Advanced Heart Failure.

end-stage heart failure myocardial work prognosis speckle tracking

Journal

Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402

Informations de publication

Date de publication:
06 Jun 2024
Historique:
received: 01 05 2024
revised: 30 05 2024
accepted: 03 06 2024
medline: 19 6 2024
pubmed: 19 6 2024
entrez: 19 6 2024
Statut: epublish

Résumé

An increasing proportion of heart failure (HF) patients progress to the advanced stage (AdHF) with high event rates and limited treatment options. Echocardiography, particularly Speckle Tracking-derived myocardial work (MW), is useful for HF diagnosis and prognosis. We aimed to assess MW's feasibility in the prognostic stratification of AdHF. We retrospectively screened patients with AdHF who accessed our hospital in 2018-2022. We excluded subjects with inadequate acoustic windows; unavailable brachial artery cuff pressure at the time of the echocardiography; atrial fibrillation; and mitral or aortic regurgitation. We measured standard parameters and left ventricular (LV) strain (LS) and MW. The population was followed up to determine the composite outcomes of all-cause mortality, left ventricular assist device implantation and heart transplantation (primary endpoint), as well as unplanned HF hospitalization (secondary endpoint). We enrolled 138 patients, prevalently males (79.7%), with a median age of 58 years (IQR 50-62). AdHF etiology was predominantly non-ischemic (65.9%). Thirty-five patients developed a composite event during a median follow-up of 636 days (IQR 323-868). Diastolic function, pulmonary pressures, and LV GLS and LV MW indices were not associated with major events. Contrarily, for the secondary endpoint, the hazard ratio for each increase in global work index (GWI) by 50 mmHg% was 0.90 ( GWI and GCW, with good feasibility, can help in the better characterization of patients with AdHF at higher risk of HF hospitalization and adverse events, identifying the need for closer follow-up or additional HF therapy.

Sections du résumé

BACKGROUND BACKGROUND
An increasing proportion of heart failure (HF) patients progress to the advanced stage (AdHF) with high event rates and limited treatment options. Echocardiography, particularly Speckle Tracking-derived myocardial work (MW), is useful for HF diagnosis and prognosis. We aimed to assess MW's feasibility in the prognostic stratification of AdHF.
METHODS METHODS
We retrospectively screened patients with AdHF who accessed our hospital in 2018-2022. We excluded subjects with inadequate acoustic windows; unavailable brachial artery cuff pressure at the time of the echocardiography; atrial fibrillation; and mitral or aortic regurgitation. We measured standard parameters and left ventricular (LV) strain (LS) and MW. The population was followed up to determine the composite outcomes of all-cause mortality, left ventricular assist device implantation and heart transplantation (primary endpoint), as well as unplanned HF hospitalization (secondary endpoint).
RESULTS RESULTS
We enrolled 138 patients, prevalently males (79.7%), with a median age of 58 years (IQR 50-62). AdHF etiology was predominantly non-ischemic (65.9%). Thirty-five patients developed a composite event during a median follow-up of 636 days (IQR 323-868). Diastolic function, pulmonary pressures, and LV GLS and LV MW indices were not associated with major events. Contrarily, for the secondary endpoint, the hazard ratio for each increase in global work index (GWI) by 50 mmHg% was 0.90 (
CONCLUSIONS CONCLUSIONS
GWI and GCW, with good feasibility, can help in the better characterization of patients with AdHF at higher risk of HF hospitalization and adverse events, identifying the need for closer follow-up or additional HF therapy.

Identifiants

pubmed: 38893722
pii: diagnostics14111196
doi: 10.3390/diagnostics14111196
pii:
doi:

Types de publication

Journal Article

Langues

eng

Auteurs

Giulia Elena Mandoli (GE)

Department of Medical Biotechnologies, Division of Cardiology, University of Siena, 53100 Siena, Italy.
Institute of Public Health and Clinical Medicine, Umeå University, 901 87 Umeå, Sweden.

Federico Landra (F)

Department of Medical Biotechnologies, Division of Cardiology, University of Siena, 53100 Siena, Italy.

Benedetta Chiantini (B)

Department of Medical Biotechnologies, Division of Cardiology, University of Siena, 53100 Siena, Italy.

Lorenzo Bonadiman (L)

Department of Medical Biotechnologies, Division of Cardiology, University of Siena, 53100 Siena, Italy.

Maria Concetta Pastore (MC)

Department of Medical Biotechnologies, Division of Cardiology, University of Siena, 53100 Siena, Italy.

Marta Focardi (M)

Department of Medical Biotechnologies, Division of Cardiology, University of Siena, 53100 Siena, Italy.

Flavio D'Ascenzi (F)

Department of Medical Biotechnologies, Division of Cardiology, University of Siena, 53100 Siena, Italy.

Matteo Lisi (M)

Department of Cardiovascular Disease-AUSL Romagna, Division of Cardiology, Ospedale S. Maria Delle Croci, 48121 Ravenna, Italy.

Enrico Emilio Diviggiano (EE)

Department of Medical Biotechnologies, Division of Cardiology, University of Siena, 53100 Siena, Italy.

Luca Martini (L)

Department of Medical Biotechnologies, Division of Cardiology, University of Siena, 53100 Siena, Italy.

Sonia Bernazzali (S)

Department of Cardiac Surgery, University of Siena, 53100 Siena, Italy.

Serafina Valente (S)

Department of Medical Biotechnologies, Division of Cardiology, University of Siena, 53100 Siena, Italy.

Massimo Maccherini (M)

Department of Cardiac Surgery, University of Siena, 53100 Siena, Italy.

Matteo Cameli (M)

Department of Medical Biotechnologies, Division of Cardiology, University of Siena, 53100 Siena, Italy.

Michael Y Henein (MY)

Institute of Public Health and Clinical Medicine, Umeå University, 901 87 Umeå, Sweden.

Classifications MeSH